We, therefore, designed this review to explore all evidence-based articles that pertain to the use of this novel drug (aldosterone synthase inhibitor) in the treatment of cardiovascular disease with special emphasis on systemic and resistant HTN. The gene discussed is CYP11B2; the disease is hypertensive disorder.